Evaluation of Responsiveness to Reduced-Dose Rituximab in Corticotropin/Intravenous Immunoglobulin/Rituximab Combination Immunotherapy for Opsoclonus-Myoclonus Syndrome
- 1 August 2018
- journal article
- research article
- Published by Elsevier BV in Pediatric Neurology
- Vol. 85, 71-75
- https://doi.org/10.1016/j.pediatrneurol.2018.05.003
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Opsoclonus Myoclonus SyndromePublished by Elsevier BV ,2017
- Effect of Increased Immunosuppression on Developmental Outcome of Opsoclonus Myoclonus Syndrome (OMS)Journal of Child Neurology, 2014
- Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS diseaseNeurology, 2014
- Pediatric Dosing of Rituximab Revisited: Serum Concentrations in Opsoclonus-myoclonus SyndromeJournal of Pediatric Hematology/Oncology, 2010
- Long-Term Cerebrospinal Fluid and Blood Lymphocyte Dynamics After Rituximab for Pediatric Opsoclonus-MyoclonusJournal of Clinical Immunology, 2009
- Rituximab and Intravenous Immunoglobulins for Relapsing Postinfectious Opsoclonus-Myoclonus SyndromePediatric Neurology, 2008
- RESPONSE TO RITUXIMAB AND PREDNISOLONE FOR OPSOCLONUS-MYOCLONUS-ATAXIA SYNDROME IN A CHILD WITH GANGLIONEUROBLASTOMAPediatric Hematology and Oncology, 2008
- Rituximab (anti-CD20) Adjunctive Therapy for Opsoclonus-Myoclonus SyndromeJournal of Pediatric Hematology/Oncology, 2006
- Response to rituximab in a child with neuroblastoma and opsoclonus‐myoclonusPediatric Blood & Cancer, 2006
- B- and T-cell markers in opsoclonus–myoclonus syndromeNeurology, 2004